skip to content

Ocrevus 300mg (IV) Ocrelizumab

Intended for healthcare professionals only

This material should not be used as a substitute for professional medical advice or to promote any medication. For more information, please consult your physician

Ocrevus is a CD20-directed cytolytic antibody indicated for the treatment of:

Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

Primary progressive MS, in adults.

Full prescribing information is available on request.
If you have a scientific query related to one of Roche's products, please contact us at [email protected]
In case of any adverse events or safety queries, please contact [email protected]

M-PK-00002297

Solutions

Pharma Products
See all Pharma Products
[Product] Ocrevus